Roche's Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion
Subcutaneous administration of Herceptin is less invasive and takes approximately 5 minutes instead of 30-90 minutes with currently approved IV administration. Roche today announced results from the Phase III HannaH study in women with HER2-positive early breast cancer (eBC) showing for the first time that a new way of giving Herceptin (trastuzumab) by subcutaneous (SC) injection leads to comparable efficacy (based on pathological complete response (pCR); complete eradication of the tumour cells in the breast) to the current way of giving the medicine by intravenous (IV) route. (Source: Roche Investor Update) read more..
source:http://www.medworm.com
No comments:
Post a Comment